Home › Cardiomyopathy › Pennsylvania › Pittsburgh
Cardiomyopathy clinical trials in Pittsburgh, PA
3 studies for Cardiomyopathy are looking for participants at sites in and around Pittsburgh (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RecruitingPhase 3
- University of Pittsburgh Medical Center, Presbyterian Hospital, Pittsburgh
The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients
RecruitingPhase 4
- UPMC, Pittsburgh
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
RecruitingPhase 3
- Allegheny General Hospital, Pittsburgh
- University of Pittsburgh Medical Center, Pittsburgh
About Cardiomyopathy
Cardiomyopathy is a disease that causes the heart to become enlarged, thick, or stiff. Read about the different types, their symptoms, and treatments.
More about Cardiomyopathy on MedlinePlus
Cardiomyopathy trials in other cities
- New York City, NY10 studies
- Boston, MA9 studies
- Washington, DC8 studies
- Rochester, MN8 studies
- Baltimore, MD7 studies
- San Diego, CA7 studies
- Richmond, VA6 studies
- Indianapolis, IN6 studies
- Dallas, TX6 studies
- Philadelphia, PA6 studies
- St. Louis, MO6 studies
- Charleston, SC6 studies
Other studies in Pittsburgh
- Non-Small Cell Lung Cancer48 studies
- Cancer (all types)41 studies
- Breast Cancer39 studies
- Colorectal Cancer32 studies
- Metastatic Cancer31 studies
- Melanoma31 studies
- Ovarian Cancer30 studies
- Endometrial Cancer23 studies
- Prostate Cancer23 studies
- Lung Cancer23 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Stroke22 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.